High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C

John H. Griffin,1 Kazuhisa Kojima,1 Carole L. Banka,2 Linda K. Curtiss,2 and José A. Fernández1

1Department of Molecular and Experimental Medicine, and 2Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA

Address correspondence to: J.H. Griffin, The Scripps Research Institute, SBR-5, 10550 N. Torrey Pines Road, La Jolla, California 92037, USA. Phone: (619) 784-8220; Fax: (619) 784-2243; E-mail: jgriffin@scripps.edu

Preliminary reports of this study were presented at the American Society of Hematology meeting in Orlando, Florida, USA (December 6–10, 1996. Blood. 88:523a), and the International Society for Thrombosis and Haemostasis Congress in Florence, Italy (June 6–10, 1997. Thromb. Haemost. 77:399a).

Received for publication August 24, 1998, and accepted in revised form November 24, 1998.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels are associated, respectively, with either increased risk or apparent protective effects for atherothrombosis. The ability of purified LDL and HDL to downregulate thrombin formation, a contributor to atherothrombotic processes, was assessed. Purified HDL, but not LDL, significantly enhanced activation of coagulation factor Va by activated protein C (APC) and protein S, and HDL stimulated protein S–dependent proteolytic inactivation of Va by APC, apparently due to cleavage at Arg306 in Va. In normal plasma, added HDL enhanced APC/protein S anticoagulant activity in modified prothrombin-time clotting assays. When the anticoagulant potency of HDL was compared with phospholipid (PL) vesicles of well-defined composition using this assay, HDL appeared qualitatively different from PL vesicles because HDL showed only good anticoagulant activity, whereas PL vesicles were rather procoagulant. When 20 normal plasmas were tested using this clotting assay, apoA-I levels correlated with anticoagulant response of a patient’s plasma to APC, causes a mild hypercoagulable state and is a risk factor for venous thrombosis (18, 19). The abnormality known as APC resistance, which is due to a subnormal anticoagulant response of a patient’s plasma to APC, causes a mild hypercoagulable state and is a risk factor for venous thrombosis (18, 19) and ischemic stroke (20, 21). The factor V (FV) polymorphism of Arg506Gln that most often causes hereditary APC resistance in venous thrombosis patients is not associated with increased risk for CAD or ischemic stroke (20, 22). Abnormalities of thrombomodulin, the cell-surface cofactor for generation of APC by thrombin, may be associated with increased risks for myocardial infarction (23).

For potent anticoagulant activity, APC and protein S require negatively charged phospholipids (PL) and Ca2+ (24–26). Therefore, this in vitro study was undertaken to examine the influence of purified HDL and LDL on the anticoagulant activities of APC and protein S. Using purified reagents and a novel clotting assay, we show that HDL is an anticoagulant cofactor that potentiates the protein anticoagulant activity of APC and protein S.

Introduction

The inverse correlation between plasma high-density lipoprotein (HDL) cholesterol (HDL-C) levels and incidence of coronary artery disease (CAD) is well documented (1–4). Molecular mechanisms responsible for the atheroprotective effects of HDL remain controversial, are most likely multifactorial, and may include, inter alia, reverse cholesterol transport to the liver, protection of low-density lipoprotein (LDL) from oxidative modification, and inhibition of cytokine-induced expression of adhesion molecules (5–10). Thrombin generation via blood coagulation pathways causing platelet activation and platelet-derived growth factor (PDGF) release, as well as fibrin deposition, may contribute to atherosclerosis (11). Elevated plasma lipids appear to be procoagulant and may be associated with either clinically significant thrombosis or elevated hematocrit markers of hypercoagulability (12–15). Little is known about the effects of plasma LDL and HDL on plasma anticoagulant mechanisms that regulate blood coagulation. The protein C pathway provides a major physiologic anticoagulant mechanism by which the proteolytically active form of the vitamin K–dependent zymogen protein C inactivates factors Va (FVα) and VIIIa (FVIIIα) in plasma (16–18). Activated protein C (APC)
C pathway. We speculate that this activity may help explain the beneficial properties of HDL against CAD.

**Methods**

**Reagents.** LDL (density = 1.019–1.063 g/ml) and HDL (density = 1.063–1.21 g/ml) were isolated from normal human plasma (nonsmoking healthy adult males) by sequential density gradient ultracentrifugation in the presence of protease inhibitors and antioxidants and then stored in DMEM, 0.3 mM EDTA at 4°C as described (27, 28). Lipoprotein concentrations were expressed as either protein- (29) or choline-containing PL concentrations (Phospholipids B kit; Wako Chemicals, Germany), and apoA-I antigen was measured using an ELISA kit (AlerCHEK Inc., Portland, Maine, USA).

Blood was obtained from routine venipuncture from 20 healthy adult volunteers (11 females and 9 males) after overnight fasting, then mixed with 0.129 M sodium citrate (one part plus nine parts blood). Plasma was prepared by centrifugation at 2,000 g at room temperature and then stored at -80°C.

Human factor Xa (FXa) and protein S were purchased from Enzyme Research Laboratory (South Bend, Indiana, USA). Variant Gln506-FV, normal FV, and prothrombin were purified from plasma (30, 31), and variant and normal FV were converted by thrombin to FVa as described (30, 32). The thrombin amidolytic substrate, CBS 34-47, was obtained from American Bio- PRODUCTS (Parsippany, New Jersey, USA); Innovin (recombinant human tissue factor reagent) from Baxter-Dade, (Miami, Florida, USA); bee venom and Naja mossambica mossambica phospholipase A1 from Sigma Chemical Co. (St. Louis, Missouri, USA); and FV-deficient plasma from George King Biomedical (Overland Park, Kansas, USA). Specific antisera to the heavy chain of FVa and purified human APC were gifts from A. Gale and A. Gruber (The Scripps Research Institute).

Normal LDL and HDL plasma concentrations (defined as 1 U/ml or as 100%) were considered equivalent to a choline-containing PL content of 0.94 mM and to protein concentrations of 0.75 mg/ml and 1.5 mg/ml, respectively.

**PL vesicles.** Purified PLs — phosphatidylethanolamine (PE), phosphatidylycerine (PS), phosphatidylcholine (PC) (Avanti Polar Scientific, Alabaster, Alabama, USA) — in chloroform were mixed at various weight ratios and then dried under nitrogen in siliconized glass tubes. After reconstituting the dried material in Tris-buffered saline (TBS) (50 mM Tris, 100 mM NaCl, 0.02% NaN3, pH 7.4), the PL-vesicle suspensions, in tubes surrounded by wet ice, were sonicated for six cycles of 30 s at 1-min intervals. PL vesicles were stored at 4°C and used within 1 month.

**FVa-inactivation assays.** FVa-inactivation studies using purified proteins involved two steps, an FVa-inactivation step and a step to quantitate residual FVa activity using either prothrombinase assays or coagulation assays.

Prothrombinase assays were performed with slight modification of protocols described previously (32). Aliquots containing FVa were withdrawn from reaction mixtures, and prothrombin activation was initiated by addition of factor Xa (1 nM final), prothrombin (1 μM final), and PL vesicles (20% PE/5% PS/75% PC) (25 μM final). At various times, aliquots were withdrawn and quenched with EDTA, and then thrombin amidolytic activity was quantitated (32). Thrombin amidolytic activity was linearly proportional to FVa between 1 and 20 pM FVa.

To study the time course of FVa inactivation, mixtures containing lipoproteins (equivalent to 200 μg PL/ml) or control buffer, 1.15 nM APC, and 300 pM FVa were incubated for 30 min at 37°C in the absence or presence of 14.5 nM protein S or control buffer. Aliquots were withdrawn at 0, 5, 15, 30, and 60 min after the addition of FVa, and residual FVa clotting activity was determined in prothrombin-time assays using 50 μl of FV-deficient plasma, 50 μl of diluted test sample, and 50 μl of Innovin. FVa at 0 min was measured using an aliquot withdrawn immediately after addition of FVa. Residual FVa activity was calculated from standard log-log calibration curves of clotting time versus [FVa] generated using purified FVa.

For protein S dose–response studies that used FXa–1-stage clotting assays to quantitate FVa, FVa (300 pM) was incubated with lipoproteins (equivalent to 270 μg PL), APC (1.44 nM), and various concentrations of protein S for 30 min at 37°C. Then 50 μl aliquots were withdrawn, added to 50 μl of FV-deficient plasma, and after 60 s at 37°C, clotting was initiated by addition of 50 μl containing FXa, CaCl2, and PL vesicles (20% PE/5% PS/75% PC) (1.15 nM, 8.3 mM, and 35 μM final concentrations, respectively). FVa activity was calculated using standard curves prepared using purified FVa.

**Immunoblot analysis.** Aliquots taken at various times from FVa-inactivation reaction mixtures were added to hot SDS solution, subsequently electrophoresed on 4%–15% gradient SDS-polyacrylamide gels, and transferred to an Immobilon membrane (Millipore Corp., Bedford, Massachusetts, USA) as described (30). After being blocked with 1% casein in TBS, the membrane was incubated for 1.5 h at room temperature with the mixture of rabbit polyclonal and murine monoclonal antibodies against the FVa heavy chain. After washing, membranes were incubated with a mixture of biotinylated anti-rabbit IgG (1 μg/ml) (Pierce Chemical Co., Rockford, Illinois, USA) and biotinylated antimouse IgG (1 μg/ml) (Pierce Chemical Co.) for 1 h, followed by streptavidin alkaline phosphatase (1 μg/ml) (Pierce Chemical Co.) for 45 min. Finally, a nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) substrate kit (Bio-Rad

---

**Figure 1**

Influence of purified HDL and LDL on inactivation of purified normal Arg506-FVa or variant Gln506-FVa by purified APC and protein S. APC was incubated 30 min at 37°C with FVa (20 pM), HDL (260 μM PL; squares), LDL (260 μM PL; circles), or control buffer lacking lipoproteins (triangles) in either the absence (a and b) or presence (c and d) of 14.5 nM protein S. Residual FVa was determined using prothrombinase assays. FVa activity from controls without APC was defined as 100%. HDL, high-density lipoprotein; LDL, low-density lipoprotein; FVa, factor Va; APC, activated protein C; PL, phospholipid.
Laboratories Inc., Hercules, California, USA) was used for detection of FVa heavy-chain fragments.

**Immunoadsorption analysis.** Murine monoclonal IgG antibodies (MAB) (2 mg) against apoA-I designated AI-11 (28), apoB-100 designated MB20 (33), or glycoprotein IIb/IIIa designated CP8 (34) (provided by Z. Ruggen, The Scripps Research Institute) were coupled to 500 μl of CNBr-activated Sepharose following manufacturer's instructions (Pharmacia Biotech Inc., Piscataway, New Jersey, USA). Control CNBr-activated Sepharose without antibody addition was prepared using the same procedures. Coupling of each MAB was >95%. To test for immunoadsorption of HDL anticoagulant activity, 1 ml of fresh (7 days old) HDL preparation (560 μM PL) was incubated overnight at 8°C with 500 μl each of Sepharose-adsorbed MABs or control Sepharose beads, then separated by centrifugation. The anticoagulant cofactor activity of each supernatant was tested using purified Gln506-FVa as follows: 50 μl of adsorbed solution was preincubated for varying times with Glm506-FVa (0.15 nM final), protein S (14.5 nM final), and APC (1.71 or 0.85 nM final) at 37°C. Aliquots were withdrawn and added to FV-deficient plasma to quantitate residual Glm506-FVa in FXa-1–stage assays. To define a standard curve for anticoagulant cofactor activity of adsorbed HDL supernatants, unadsorbed diluted HDL (400, 100, 25, and 0 μg/ml PL) was assayed for ability to enhance the rate of inactivation of Glm506-FVa using conditions given above and 5.1 nM APC. A standard curve was constructed based on the relationship between HDL concentration and initial rate of inactivation of Glm506-FVa. The amount of residual anticoagulant cofactor activity of each adsorbed HDL preparation was quantitated based on this standard curve. To quantify the amount of apoA-I protein adsorbed by the AI-11 MAB/Sepharose, 4%–15% gradient SDS-PAGE was used to analyze 10 μl of each of the adsorbed fractions. Protein bands were stained with ISS Pro-Blue stain (Integrated Separation System, Natick, Massachusetts, USA), and the band intensity of apoA-I was quantitated by scans using an Eagle Eye II (Stratagene, La Jolla, California, USA) (courtesy of D. Salomon, The Scripps Research Institute).

**Anticoagulant cofactor clotting assay.** To determine anticoagulant or procoagulant activities of HDL, LDL, or PL vesicles, prothrombin-time assays were performed using an Amelung KC 4A micro apparatus (Sigma Diagnostics, St. Louis, Missouri, USA); 7.5 μl normal plasma was mixed with 25 μl containing fibrinogen (4 mg/ml) and APC (96 nM) or buffer (TBS/2% BSA), 50 μl of HDL, LDL PL vesicles, or buffer, and 25 μl of protein S (420 nM) or buffer, and incubated 3 min at 37°C. Clotting times were measured after addition of 50 μl containing 1:64 or 1:40 dilution of recombinant human tissue factor (Innovin; Baxter-Dade), 30 mM CaCl2, and TBS/2% BSA. For studies of the anticoagulant response to APC/protein S of 20 normal plasmas, the clotting response to APC/protein S was compared with those using Arg506-FVa and of the variant Gln506-FVa are seen in Fig. 1. For normal Arg506-FVa, data (Fig. 1, a and c) show that HDL but not LDL markedly enhanced APC-dependent loss of FVa activity and that this anticoagulant effect of HDL was more pronounced in the presence of protein S.

To clarify the importance of HDL for cleavage at Arg306, experiments using purified Glm506-FVα variant were compared with those using Arg506-FVα (Fig. 1). Inactivation of the FVα variant is due to specific cleavage at Arg306 because APC does not cleave at Gln506 (25, 30, 37). Without protein S (Fig. 1b), no inactivation of Glm506-FVa by APC was seen in the absence or presence of HDL or LDL. However, in the presence of protein S, LDL-dependent inactivation of Glm506-FVa by APC was observed (Fig. 1d). These results suggest that protein S, along with HDL, is responsible for proteolytic inactivation of FVα because of cleavage at Arg306 by APC (vide infra).

**Results**

**Influence of HDL or LDL on APC anticoagulant activity.** To determine the influence of purified HDL and LDL fractions on anticoagulant activities of the protein C pathway, inactivation of purified coagulation FVα by APC and its cofactor, protein S, was studied using a two-step procedure. First, FVα was incubated with LDL, HDL or buffer, APC, and protein S to inactivate FVα. Second, residual FVα activity was quantitated using either prothrombinase assays or coagulation assays that employed FV-deficient plasma. The effects of purified lipoproteins on the APC dose–responses for inactivation of normal Arg506-FVa and of the variant Gln506-FVα are seen in Fig. 1. For normal Arg506-FVa, data (Fig. 1, a and c) show that HDL but not LDL markedly enhanced APC-dependent loss of FVa activity and that this anticoagulant effect of HDL was more pronounced in the presence of protein S.
Influence of purified HDL and LDL on FVa cleavage by APC and protein S. During proteolytic activation, APC cleaves the FVa heavy chain at Arg506, Arg306, and perhaps Arg679; cleavage at Arg306 is critical for complete inactivation of FVa or FV (25). Protein S and PL vesicles each enhance more than 10-fold Arg506 cleavage, whereas protein S does not markedly enhance Arg506 cleavage (25, 26). Immunoblotting studies performed using anti-FVa heavy-chain antibodies (Fig. 4) showed that APC/protein S caused a time-dependent appearance of 78-kDa bands, representing the residues 1–506 fragment (25, 26), in reaction mixtures containing HDL, LDL, or control buffer. Thus, neither HDL nor LDL appeared to markedly affect the rate of cleavage of FVa by APC at Arg506. However, only in the presence of HDL was there a time-dependent appearance of 44- and 30-kDa bands (Fig. 4) representing bands typical of the residues 1–306, 307–506, and 507–709 fragments, respectively (25, 26, 30). In parallel studies in the presence of APC but absence of protein S, immunoblots showed a time-dependent appearance of the 78-kDa band but no smaller 44- and 30-kDa bands (data not shown), indicating that under these experimental conditions protein S was required for cleavage at or near Arg506. In the absence of APC, no FVa fragments were generated (data not shown).

Requirement for phospholipids and apoA-I in HDL. The enhancement of APC-dependent anticoagulant activity by HDL seen above resembles the action of anionic PLs, which enhance protein S-dependent cleavage at Arg306 in FVa by APC (26). To assess whether PL in HDL was necessary for its anticoagulant cofactor activity, HDL was tested in dose–response studies for their ability to enhance FVa inactivation by APC and protein S (Fig. 3b). In the presence of APC and protein S, 50% inactivation of FVa required 10 µM of HDL-PL extract or 15 µM LDL-PL extract, respectively (Fig. 3b). This can be compared with 70 µM of HDL or >1.5 mM LDL required for 50% FVa inactivation (Fig. 3a), suggesting that purified HDL is about 15% as active as its component PL extract, whereas LDL is less than 1% as active as its component PL extract.

PL extracts were prepared from purified LDL and HDL and tested in dose–response studies for their ability to enhance FVa inactivation by APC and protein S (Fig. 3b). For example, HDL at 0.4 mM PL equivalent supported 45% and 80% loss of FVa activity by APC alone and APC plus protein S, respectively (Fig. 3a). In the absence of lipoproteins, no measurable FVa inactivation occurred under the conditions employed. In the presence of LDL, APC in the presence or absence of protein S caused at most only modest inactivation of FVa, and HDL was clearly much more active than LDL. For example, in the presence of APC and protein S, 40% loss of FVa activity was observed at 43 µM PL/HDL and at 1.3 mM PL/LDL, suggesting that HDL was ~30 times more active than LDL when compared on the basis of choline-containing PL content. The highest HDL and LDL concentrations studied in Fig. 3a correspond to ~135% of normal plasma levels of HDL or LDL, i.e., equivalent to 1.3 mM choline-containing PL versus the normal plasma values equivalent to 0.94 mM choline-containing PL. Thus, these results show that HDL at levels present in normal plasma can support significant APC anticoagulant activity in the presence of protein S.

Figure 3
Influence of purified HDL and LDL or of their PL extracts on inactivation of FVa by APC and protein S. (a) HDL (squares) or LDL (circles) were incubated with FVa (20 pmol) for 30 min with 350 pmol APC alone (open symbols), 350 pmol APC and 14.5 nM protein S (solid symbols), or control buffer (HDL, solid triangles; LDL, open triangles). Residual FVa was measured using prothrombinase assays. FVa activity without HDL or LDL was defined as 100% activity. (b) PL extracts from HDL (squares) or LDL (circles) were tested for their ability to enhance FVa inactivation using the same reagents and conditions as in a. Symbols represent the same variables (APC alone, APC plus protein S, or control buffer) as in a. Concentrations of LDL and HDL or their PL extracts are given based on content of choline-containing PL.

cofactor activity, FVa was incubated with a low level of APC and lipoproteins or buffer at varying protein S concentrations for 30 min, and then residual FVas was quantitated using prothrombinase assays (Fig. 2a) or FXa-1–stage clotting assays (Fig. 2b). HDL, but not LDL, enhanced the anticoagulant activity of protein S, and the quantitation of loss of FVa activity was essentially the same based on either prothrombinase assays (Fig. 2a) or FXa-1–stage clotting assays (Fig. 2b). Under the conditions employed, no FVa inactivation was observed in the presence of LDL or in the absence of lipoproteins (Fig. 2) or APC (data not shown). Under the conditions employed, 7.3 nM protein S was required for >50% inhibition of FVas by APC. Free protein S, which exhibits APC-cofactor activity, is present in normal human plasma at 145 nM (38), indicating that the protein S effects could occur within its physiological range.

Dose dependence for anticoagulant activity of HDL or LDL or their PL extracts. To define the influence of HDL and LDL concentrations on FVa inactivation, experiments similar to those above were performed (Fig. 3a). HDL at or below plasma levels showed potent anticoagulant cofactor activity (i.e., loss of FVa activity) when either APC alone or APC plus protein S were present (Fig. 3a, lower two curves). For example, HDL at 0.4 mM PL equivalent supported 45% and 80% loss of FVa activity by APC alone and APC plus protein S, respectively (Fig. 3a). In the absence of lipoproteins, no measurable FVa inactivation occurred under the conditions employed. In the presence of LDL, APC in the presence or absence of protein S caused at most only modest inactivation of FVa, and HDL was clearly much more active than LDL. For example, in the presence of APC and protein S, 40% loss of FVa activity was observed at 43 µM PL/HDL and at 1.3 mM PL/LDL, suggesting that HDL was ~30 times more active than LDL when compared on the basis of choline-containing PL content. The highest HDL and LDL concentrations studied in Fig. 3a correspond to ~135% of normal plasma levels of HDL or LDL, i.e., equivalent to 1.3 mM choline-containing PL versus the normal plasma values equivalent to 0.94 mM choline-containing PL. Thus, these results show that HDL at levels present in normal plasma can support significant APC anticoagulant activity in the presence of protein S.
μM PL) was pretreated for 15 minutes at 37°C with purified phospholipase A2 from either bee venom (1.8 nM) or Naja mossambica mossambica venom (0.45 nM) before addition of APC (0–340 pM) and FVa (20 pM) in the absence or presence of protein S (29 nM). After 30 minutes, residual FVas was quantitated essentially as described (Fig. 1). In results not shown, each phospholipase A2 ablated the anticoagulant cofactor activity of HDL, suggesting that intact PL in HDL was necessary.

To define the active molecular species in HDL, immobilized antibodies against apoA-I, apoB-100, or glycoprotein IIbIIIa were tested for their ability to adsorb anticoagulant activity. Anti–apoA-I IgG adsorbed 80% of the anticoagulant activity, whereas no significant (<8%) adsorption was observed for the other antibodies or control Sepharose beads (data not shown). Based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and densitometric analyses, immobilized anti–apoA-I antibody adsorbed the target apoA-I antigen; i.e., the stained apoA-I protein band seen for the supernatant of HDL samples adsorbed with anti–apoA-I/Sepharose was 14% of the band seen for parallel HDL samples adsorbed with control Sepharose beads or with Sepharose beads containing immobilized MABs against apoB-100 or glycoprotein IIbIIIa. Thus, HDL containing apoA-I provided the anticoagulant activity observed, and anticoagulant activity was not due to contamination of HDL with glycoprotein IIbIIIa-bearing platelet microparticles.

HDL anticoagulant activity in clotting assays of normal plasma. To demonstrate the anticoagulant cofactor activity of HDL in the plasma milieu, a modified prothrombin-time clotting assay was developed. As seen in Fig. 5, in the presence of APC and protein S, addition of purified HDL caused dose-dependent marked prolongation of this modified prothrombin-time assay whereas LDL had only a slight effect. For example, when HDL in the clotting assay mixture was increased from only a slight effect. For example, when HDL in the clotting assay mixture was increased from a 28-second prolongation to a 40-second prolongation when protein S was present in the absence of added APC, neither HDL nor LDL had any effect on the clotting times (data not shown). When the anticoagulant activity of HDL prepared from six unrelated blood donors was assayed in HDL dose–response studies as in Fig. 5, similar results were obtained (data not shown). Based on the HDL dose–response curves, the variation in HDL specific activity was <40% among the six donors’ HDL preparations (data not shown). Thus, HDL purified from six different donors showed similar significant anticoagulant cofactor activity when APC and protein S were added.

Experiments were performed to characterize the anticoagulant potency of HDL compared with PL vesicles of well-defined composition. The dilute prothrombin time was determined in the absence and presence of APC and protein S at varying concentrations of PL vesicles containing either 20% PS/80% PC or 1% PS/3% PE/96% PC, the former being optimal for PL-dependent coagulation reactions and the latter containing the known PS and PE content of HDL. The results in Fig. 6 show that the PL vesicles appeared procoagulant only below 25 μM and above 25 μM appeared anticoagulant in the absence or presence of APC and protein S. The ratio of the clotting time in the presence of added APC and protein S to that observed in their absence reflects the anticoagulant response to APC/protein S. When ratios for PL vesicles were compared with those for HDL (Fig. 6, inset), it appeared that HDL was qualitatively different from the two PL vesicles because HDL showed good anticoagulant activity but no procoagulant activity, whereas the PL vesicles were essentially rather procoagulant and gave a ratio <3.0, the ratio observed for no PL or HDL additions. On net balance, the anticoagulant activity of HDL added to plasma was much greater than the activity of these vesicles; e.g., at 400 μM PL, the ratio was >5 for HDL but only 2.0–2.1 for PL vesicles (less than control with no added PL). Moreover, it was clear that HDL up to 1,000 μM PL exhibited no procoagulant activity in the absence of APC and protein S, whereas vesicles with the 1% PS/3% PE content of HDL, which shortened the clotting time from 52 seconds to 40 seconds at 400 μM PL (Fig. 6), were procoagulant.

To assess the correlation between endogenous HDL plasma levels and anticoagulant response to APC/pro-
tein S, fasting plasma samples from 20 healthy adults were tested using the modified prothrombin-time assay. The level of apoA-I antigen was determined as an indicator of HDL protein in each plasma. The anticoagulant response to added APC/protein S was correlated with the level of apoA-I ($r = 0.47, P = 0.035$) (Fig. 7a). However, given the obvious variability and scatter in these data, a number of other plasma factors contribute to the variability in anticoagulant response in APC/protein S. The standard APTT-based APC resistance test was also performed on parallel plasma samples from the same 20 blood donations. In contrast to the prothrombin time–based test results (Fig. 7a), there was no statistically significant correlation between the APTT-based APC resistance ratio and plasma apoA-I levels ($r = 0.12, P = 0.63$) (Fig. 7b). Moreover, comparison of the prothrombin time–based APC/protein S sensitivity test results with the APTT-based APC resistance ratio showed no statistically significant correlation ($r = 0.25, P = 0.26$).

Discussion

Experiments reported here demonstrate for the first time that HDL, a generally beneficial heterogeneous fraction of plasma lipoproteins, can significantly enhance anticoagulant activity exerted by APC and protein S. Studies using purified lipoproteins and coagulation factors show that HDL but not LDL enhances APC inactivation of FVa as well as protein S cofactor activity for this reaction. Results for quantitation of FVa inactivation obtained using clotting assays were consistent with results from prothrombinase assays. When different preparations of protein S or HDL from different healthy adult donors were used, the same results were observed. Thus, the conclusion that HDL is an anticoagulant cofactor in purified reaction mixtures was not dependent on either the method used to quantitate FVa inactivation or the donor of purified reagent lipoproteins or clotting factors. The anticoagulant cofactor activity of HDL preparations is indeed due to the HDL particles, because anti–apoA-I antibodies adsorbed the activity while anti-glycoprotein IIbIIIa and anti–apoB-100 antibodies had no effect.

Dose-dependent anticoagulant activity of purified HDL is demonstrable in the plasma milieu in the presence, but not the absence, of APC and protein S when dilute tissue factor is used to initiate clotting (Fig. 5). Moreover, the anticoagulant response to added APC/protein S in our modified prothrombin-time assay is correlated with the level of apoA-I (Fig. 7a), the major protein of HDL. The latter observation supports the conclusion that apoA-I bearing HDL particles are responsible for the anticoagulant cofactor activity of purified HDL. The coefficient of determination for apoA-I and anticoagulant response to APC/protein S is 0.22, suggesting that, at least in vitro, plasma HDL levels may exert a significant influence on the anticoagulant response of the protein C pathway.

The dilute prothrombin-time assay in which both the tissue factor reagent and the test plasma are diluted and to which we add fibrinogen was developed to be sensitive to endogenous plasma lipids and lipoproteins in its response to APC/protein S. Standard APTT assays involve addition of PL reagents that tend to mask the procoagulant and anticoagulant properties of endogenous plasma lipids. Furthermore, the standard APTT-based APC resistance test is not sensitive to added protein S (39), whereas protein S addition permits marked HDL influence on our prothrombin time–based APC sensitivity assay (Fig. 5). Interestingly, the traditional APTT-based APC resistance test results are not significantly correlated either with apoA-I levels (Fig. 7b) or with the response to APC/protein S measured using the dilute prothrombin-time clotting assay. Therefore, published information about risks of thrombotic disease associated with “APC resistance” that was diagnosed using APTT-based assays involving either neat patient plasma (35) or patient plasma diluted into FV-deficient plasma (40) cannot simply be extrapolated to the relationship between prevalence or risk of thrombotic diseases and sensitivity to APC/protein S diagnosed using our prothrombin time–based assay. In general terms, the in vitro anticoagulant response to APC in different clotting assays may be more or less sensitive to plasma components, depending on the design of the clotting assay. Hence, the terms APC resistance or APC sensitivity should be carefully qualified in the context of the experimental conditions.

As a corollary to the proposed relationship between HDL and the anticoagulant protein C pathway, one might speculate that protein C or protein S deficiency would predispose a patient to atherosclerosis. No adult with severe homozygous deficiency for either of these autosomal traits has been identified. The majority of surviving homozygous protein C–deficient children are quite young and do not provide informative data regarding this speculation. Although reports of arterial thrombosis associated with protein C and protein S heterozygous deficiency have appeared (41–43), it has not been established that heterozygous deficiency of these pro-
teins is a predisposing risk factor. Although one might look for an inverse correlation between zymogen protein C antigen level and incidence of coronary heart disease, no such relationship was found in the Atherosclerosis Risk in Communities (ARIC) study (44). However, we note that HDL modulates the anticoagulant response to APC/protein S and that this response does not depend on the level of protein C zymogen. Interestingly, the relative risk of ischemic stroke in the ARIC study was inversely correlated with protein C levels (45), suggesting that protein C is neuroprotective for cerebral arterial thrombosis. New appropriately designed clinical and animal model studies are needed to assess the hypothesis that HDL may modulate the expression of protein C pathway activities, especially in the brain. One might also ask whether high HDL is protective with respect to venous thrombosis; we are unaware of any useful study of this question. Hyperlipidemia is apparently a risk factor for venous thrombosis (46). One should note that mechanisms for pathophysiology of arterial disease, including arterial thrombosis, only partially overlap those for venous disease and venous thrombosis.

Limited proteolysis of the FVa heavy chain by APC was studied using immunoblot analysis to clarify the mechanisms by which HDL contributes to APC anticoagulant activity. APC inactivates FVa by cleavage first at Arg506, then at Arg306 (25), the latter but not the former cleavage being greatly enhanced by protein S (26). Overall, the results from functional assays (Fig. 1) and immunoblot studies (Fig. 4) are consistent with the hypothesis that interactions involving both protein S and HDL contribute to APC activity by promoting FVa cleavage specifically at Arg306.

When the net procoagulant and/or anticoagulant activity of HDL added to plasma was compared with PL vesicles (Fig. 6), synthetic PL vesicles containing either 20% PS/80% PC or 1% PS/3% PE/96% PC were procoagulant, whereas HDL was anticoagulant. Thus, there are both qualitative and quantitative differences between HDL and PL vesicles in these clotting assays. Thus, HDL does not simply provide a PL surface as do PL vesicles, and HDL appears to have unique anticoagulant cofactor properties.

Because phospholipase A2 abrogates the activity, PL is essential for HDL’s anticoagulant action. When PL extracts of purified HDL and LDL were normalized for choline-containing PL and compared for their ability to support APC and protein S activity, they were similar, with HDL-PL being 1.5-fold more active than LDL-PL (Fig. 3b). However, when HDL and LDL were similarly compared, HDL was ~30 times more active than LDL (Fig. 3a). HDL had ~15% the activity of its PL extract, whereas LDL had <1% of its PL activity, suggesting that incorporation of PL into these lipoproteins markedly restricts the availability of PL to support coagulation reactions. Because the overall PL content and composition of HDL particles are not significantly different from those of LDL, it is unclear why HDL but not LDL particles provide a supporting surface for the action of protein S and APC. The anticoagulant effect of HDL may result from high affinity of protein S for HDL particles due to some unique structural HDL properties, such as size of particles and content of lipids and/or PLs, and/or qualitative differences, such as net charge or polarity. Alternatively or additionally, the apolipoproteins of HDL may organize PL into domains that favor interaction with protein S, APC, and/or FVa. HDL’s apolipoproteins may interact specifically with APC, protein S, or FVa. The chemical heterogeneity of HDL particles underlies their multiple and variable functional properties.

In vitro studies have shown that APC-dependent anticoagulant activity in the presence of protein S is significantly enhanced by PE (47) or cardiolipin (Fernández, J.A., et al., unpublished data) when either is incorporated into multicomponent PL vesicles. It was suggested that these two PLs are more anticoagulant than procoagulant, at least in the presence of APC and protein S, suggesting that PL composition of vesicles may alter their hemostatic properties. In extending this concept to HDL particles, we speculate that PE and/or cardiolipin as anticoagulant PLs may contribute to the anticoagulant APC/protein S cofactor activity of HDL. It would follow that HDL subfractions enriched in PE and/or cardiolipin may possess a higher specific activity as an anticoagulant cofactor. Patients with CAD have lower HDL-PL levels (48, 49), and decreases in HDL-PL levels were reported to correlate better with CAD than with the decrease in HDL-cholesterol.

Figure 6 Comparison of HDL anticoagulant potency with PL vesicles. The modified prothrombin-time assay was performed in the absence (open symbols) and presence (solid symbols) of added APC/protein S (see Methods) and varying concentrations of HDL (circles), PL vesicles containing 20% PS/80% PC (diamonds), or 1% PS/3% PE/96% PC (triangles). Squares indicate absence of added HDL or PL. Inset shows the ratio of the clotting time in the presence of added APC/protein S to that without added APC/protein S.

The Journal of Clinical Investigation | January 1999 | Volume 103 | Number 2 225
levels (50). Furthermore, HDL in plasma of subjects with high HDL levels has relatively higher levels of PE than HDL in subjects with normal HDL levels (51). These observations are consistent with a physiological role for HDL-PL in the regulation of atherothrombosis.

Based on the present study involving purified reagents, we propose that the atheroprotective activity of plasma HDL may be based, at least in part, on HDL’s ability to promote procoagulant reactions and thrombin generation. The new hypothesis that HDL exerts APC/protein S–dependent anticoagulant activity supports a paradigm in which plasma lipids and lipoproteins can promote procoagulant reactions and thrombin generation. The new hypothesis that HDL exerts APC/protein S–dependent anticoagulant activity supports a paradigm in which plasma lipids and lipoproteins can promote procoagulant reactions and thrombin generation.

Acknowledgments

Helpful discussions with M.J. Heeb and Y. Kojima, who also provided Gln506–FVa, are gratefully acknowledged. This study was supported in part by National Institutes of Health grants ROIHL21544, R37HL52246, RO1HL43815, RO1HL50060, and MO1RR00833, and by the Stein Endowment Fund.

Figure 7

Correlation between plasma apoA-I levels and anticoagulant response to either (a) APC/protein S in prothrombin-time assays or (b) APC in APTT assays. Levels of apoA-I antigen were measured in 20 normal healthy adult plasma (11 females, 9 males) and analyzed for correlation with either (a) anticoagulant response to APC/protein S in dilute prothrombin-time assays or (b) anticoagulant response to APC in APTT assays (35, 36). Anticoagulant response is reported as the ratio of the clotting time observed in the presence of added (a) APC/protein S or (b) APC alone to the respective control clotting time observed in the absence of added anticoagulant factors. Statistical analysis: (a) r = 0.47, P = 0.035; (b) r = −0.12; P = 0.63. APTT, activated partial thromboplastin time.


